Oncology

SK pharmteco signs agreement to manufacture Ferring’s ADSTILADRIN

Ferring Pharmaceuticals and SK pharmteco have entered into an agreement to increase commercial manufacturing capacity for Ferring’s ADSTILADRIN (nadofaragene firadenovec-vncg), ensuring a long-term supply of the non-replicating adenoviral vector-based gene therapy.

NICE recommends Novartis’ CAR-T therapy for leukaemia

The UK National Institute for Health and Care Excellence (NICE) has recommended the routine use of Novartis' tisagenlecleucel (Kymriah), a chimeric antigen receptor T-cell (CAR-T) therapy, for children and young adults aged up to 25 years with B-cell acute lymphoblastic leukaemia (ALL).

TORL BioTherapeutics secures $158m for oncology pipeline development

Clinical-stage biotechnology company TORL BioTherapeutics has announced the closure of an oversubscribed $158m Series B-2 financing round.

Teva signs licensing deal with mAbxience for oncology biosimilar candidate

Teva Pharmaceuticals International, a subsidiary of Teva Pharmaceutical Industries, has entered into a strategic licensing agreement with mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma.

Alterome Therapeutics secures $132m in Series B funding

Alterome Therapeutics, a biopharmaceutical company, has closed a $132m Series B financing round.

AstraZeneca signs agreement to acquire Fusion Pharmaceuticals

AstraZeneca has announced its definitive agreement to acquire Fusion Pharmaceuticals, a move set to bolster its oncology portfolio with innovative radioconjugates (RCs).

FDA committee recommends BMS-2seventy’s Abecma

The US Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) has voted in favour of Bristol Myers Squibb (BMS) and 2seventy bio’s Abecma (idecabtagene vicleucel) for treating triple-class exposed relapsed or refractory multiple myeloma.

Tubulis secures $138.8m to develop ADCs for solid tumours

Tubulis has secured €128m ($138.8m) in a Series B2 financing round to expedite the clinical development of its antibody drug conjugates (ADCs) pipeline, focused on solid tumours.

FDA grants orphan drug status to Poseida’s multiple myeloma therapy

Poseida Therapeutics has received the US Food and Drug Administration’s (FDA) orphan drug designation for its new chimeric antigen receptor (CAR)-T therapy candidate, P-BCMA-ALLO1, to treat multiple myeloma.